IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
SOUTH SAN FRANCISCO, Calif., March 14, 2022 -- (Healthcare Sales & Marketing Network) -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted ther... Biopharmaceuticals, Oncology IDEAYA Biosciences, Pfizer, darovasertib, crizotinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Clinical Trials | Eye Cancers | Marketing | Melanoma | Pfizer | Pharmaceuticals | Skin Cancer | Uveal Melanoma